Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Highly efficient therapeutic gene editing of human hematopoietic stem cells.

Wu Y, Zeng J, Roscoe BP, Liu P, Yao Q, Lazzarotto CR, Clement K, Cole MA, Luk K, Baricordi C, Shen AH, Ren C, Esrick EB, Manis JP, Dorfman DM, Williams DA, Biffi A, Brugnara C, Biasco L, Brendel C, Pinello L, Tsai SQ, Wolfe SA, Bauer DE.

Nat Med. 2019 May;25(5):776-783. doi: 10.1038/s41591-019-0401-y. Epub 2019 Mar 25.

2.

Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients.

Esrick EB, Manis JP, Daley H, Baricordi C, Trébéden-Negre H, Pierciey FJ, Armant M, Nikiforow S, Heeney MM, London WB, Biasco L, Asmal M, Williams DA, Biffi A.

Blood Adv. 2018 Oct 9;2(19):2505-2512. doi: 10.1182/bloodadvances.2018016725.

3.

Genetic therapies for sickle cell disease.

Esrick EB, Bauer DE.

Semin Hematol. 2018 Apr;55(2):76-86. doi: 10.1053/j.seminhematol.2018.04.014. Epub 2018 May 7. Review.

PMID:
29958563
4.

Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea.

Okam MM, Esrick EB, Mandell E, Campigotto F, Neuberg DS, Ebert BL.

Blood. 2015 Jun 4;125(23):3668-9. doi: 10.1182/blood-2015-03-635391. No abstract available.

5.

Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation.

Esrick EB, McConkey M, Lin K, Frisbee A, Ebert BL.

Am J Hematol. 2015 Jul;90(7):624-8. doi: 10.1002/ajh.24019. Epub 2015 May 28.

6.

Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing.

Xu J, Peng C, Sankaran VG, Shao Z, Esrick EB, Chong BG, Ippolito GC, Fujiwara Y, Ebert BL, Tucker PW, Orkin SH.

Science. 2011 Nov 18;334(6058):993-6. doi: 10.1126/science.1211053. Epub 2011 Oct 13.

Supplemental Content

Loading ...
Support Center